ABSTRACT
agents is also attributable to poor penetration of the biofilm by ostensibly effective antibiotics [5] . In the setting of pulmonary tuberculosis (TB), the sessile organisms are insulated in sac-like granuloma lesions, somewhat similar to encasement in biofilm observed in in vitro cultures [6] [7] [8] . During TB chemotherapy with rifampicin and isoniazid, planktonic bacteria are killed rapidly (within 2 weeks), whilst eradication of sessile organisms necessitates extended exposure to higher concentrations of these agents [1, 4, 9] . Clearly, antibiotics that penetrate the biofilm and/or inhibit its formation [10, 11] have the potential to improve the efficacy of TB chemotherapy.
The antimycobacterial riminophenazine agent clofazimine is categorised by the World Health Organization (WHO) as a last-resort option (group 5 drug) in the treatment of multidrug-resistant TB (MDR-TB), largely because of its poor pharmacokinetic properties [12, 13] . However, this antibiotic possesses several properties that may enable it to target both biofilm-forming as well as biofilminsulated organisms, including those that are MDR [12] [13] [14] . Foremost amongst these are its lipophilicity and low-level resistance profile, as well as recently described inhibitory activity against mycobacterial persisters [15] [16] [17] [18] . To address this issue, this study was undertaken with the primary objectives of determining: (i) the minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of clofazimine against actively growing planktonic and slowly replicating biofilm-producing mycobacteria as well as non-replicating biofilm-encased organisms; and (ii) the inhibitory effects of clofazimine both on biofilm formation and the structural resilience of pre-formed biofilm.
Materials and methods

Strains and growth media
Mycobacterium tuberculosis H37Rv ATCC 25618 and Mycobacterium smegmatis were prepared following the manufacturers' instructions, whilst Sauton broth was prepared as described previously [1] .
Chemicals, reagents and antibiotics
Unless otherwise stated, all other chemicals and reagents, including clofazimine, were purchased from Sigma Chemical Co. (St Louis, MO, USA). Clofazimine was dissolved in dimethyl sulphoxide (DMSO) and was used at concentrations ranging from 0.01 mg/L to 20 mg/L. The final concentration of DMSO in the drug-containing and control systems was 1%, and solvent controls were included in all experiments.
Inoculum preparation
Mycobacterium tuberculosis and M. smegmatis were inoculated into 7H9 broth and were incubated at 37 C for 7 days or 24 h under stirring conditions, respectively. Thereafter, the cultures were centrifuged at 3500  g for 10 min at room temperature and the supernatants were discarded. The pellets were washed twice, re-suspended in Sauton broth and the optical density at 540 nm was adjusted to 0.6, yielding ca. 
Minimum inhibitory concentration determination
The MICs of clofazimine for M. tuberculosis and M. smegmatis were determined using broth and plate dilution procedures in a BACTEC TB system (Becton Dickinson Co., Maryland, USA) and on 7H10 plates, respectively, based on the proportion method as described previously [19, 20] . The clofazimine concentrations used ranged from 0.01 mg/L to 5 mg/L. For M. tuberculosis, the procedure used was as described previously [19] . In the case of M. smegmatis, the various concentrations of clofazimine were incorporated into 7H10 agar plates. One set of drug-free and all drug-containing plates were inoculated with 10 4 CFU/mL, whilst another set of drug-free plates, serving as controls, was inoculated with 100 dilution of the inoculum (10 2 CFU/mL). The plates were incubated at 37 C for 72 h to allow for the appearance of colonies. The lowest concentration of the drug that yielded fewer colonies than those that grew on the 100 diluted controls was regarded as the MIC. The rates of growth of the bacteria were determined by sampling, diluting and plating the cultures every 24 h and 6 h for M. tuberculosis and M. smegmatis planktonic organisms, respectively, and bi-/weekly or daily for biofilm bacilli for each mycobacterial species, and monitoring thereafter for the appearance of colonies, which were compared with the number of viable bacteria in the initial inoculum.
Planktonic and biofilm culture preparation
Minimum bactericidal concentration determination and rate of killing
Clofazimine MBCs were determined for planktonic and biofilm cultures of both smegmatis, respectively. The MBC was regarded as the lowest concentration of clofazimine showing 2 log reduction in CFU/mL of the initial inoculum (Day 0) [20] .
Biofilm quantification
Biofilms were quantitated using a crystal violet-based staining procedure [23] .
Supernatants were removed and the residual biofilm biomasses were washed twice with distilled water and were air-dried. Crystal violet (1%) was added to each well and was incubated for 30 min at room temperature. Unbound dye was removed by washing with distilled water and the wells were air-dried. The residue was dissolved and the crystal violet was extracted in 70% ethanol, diluted and the optical density at 570 nm was measured using a Unicam Heλios- UV spectrophotometer (Thermo Scientific, Waltham, MA, USA).
Statistical analyses
Results are expressed as the mean ± standard error of the mean for each series of experiments. Statistical analysis was performed using GraphPad InStat 3 (GraphPad Software Inc., La Jolla, CA). All figures were plotted using GraphPad Prism v.5
(GraphPad Software Inc.).
Results
Minimum inhibitory concentrations of clofazimine for planktonic bacilli
Using broth and plate dilution methods, clofazimine demonstrated dose-related inhibition of the growth of M. tuberculosis and M. smegmatis, with MICs of 0.06 mg/L and 2.5 mg/L, respectively.
Minimum bactericidal concentrations of clofazimine for planktonic bacilli
MBCs of clofazimine for planktonic bacilli are shown in 
Activity of clofazimine against biofilm-producing mycobacterial bacilli
The activity of clofazimine against biofilm-producing mycobacterial bacilli is shown in 
Activity of clofazimine against biofilm-encased mycobacteria
The activity of clofazimine against biofilm-encased mycobacteria is shown in Fig. 3 .
Following biofilm formation, the biofilm-encased bacteria were treated with clofazimine and the numbers of surviving organisms were measured weekly or daily thereafter for 5 weeks or 5 days for M. tuberculosis and M. smegmatis, respectively.
In the control wells, the numbers of bacteria remained unchanged at concentrations of 1.5  10 6 ± 3.7  10 5 CFU/mL and 2.1  10 9 ± 1.1  10 9 CFU/mL for M.
tuberculosis and M. smegmatis, respectively. The observed absence of an increase in the number of bacilli in the biofilm-encased populations is consistent with the existence of predominantly non-replicating organisms that were unresponsive to clofazimine.
Effects of clofazimine on mycobacterial biofilm formation
The effects of clofazimine on mycobacterial biofilm formation are shown in 
Effects of clofazimine on pre-formed mycobacterial biofilm biomass
The effects of clofazimine on pre-formed mycobacterial biofilm biomass are shown in 
Discussion
The mg/L. However, it should also be noted that the exponentially growing cells were generated in a different medium (7H9) from that for biofilm production and the differences in effects of the antibiotic may be related not only to growth rates but also to the culture conditions.
Of the three types of microbial populations tested, the slowly replicating biofilmproducing bacilli of both mycobacterial species were found to be most susceptible to These findings are essentially in agreement with a recent study reported by Irwin et al. who described the differential efficacy of clofazimine monotherapy in several murine models of experimental pulmonary TB [24] . Clofazimine was found to be most effective against the rapidly growing, intracellular bacilli in multifocal, coalescing lesions in the lungs of BALB/c mice as well as extracellular bacilli in the initiation phase of granuloma formation in C3HeB/FeJ mice [24] . However, clofazimine was ineffective against extracellular bacilli encased in the well established, hypoxic, caseous, necrotic granulomas in the lungs of C3HeB/FeJ mice [24] .
The findings of the current study taken together with those of Irwin et al. [24] and others [16, 25] suggest that clofazimine and other antimycobacterial agents may be most effective in well aerated environments, seemingly consistent with the involvement of endogenously generated reactive oxygen species in antimicrobial activity. However, alternative mechanisms of clofazimine-mediated antimicrobial activity, probably also negated by dormancy, have also been proposed [15, 19] .
Irrespective of mechanisms of antimicrobial activity, of which there may be several, a number of clinical trials support the inclusion of clofazimine in the multidrug therapy of drug-resistant TB. When used throughout the entire treatment period, addition of clofazimine has been reported to improve cure rates in the setting of a shorter duration of treatment [14, 26, 27] . Importantly, similar treatment outcomes both for MDR-TB and extremely drug-resistant TB (XDR-TB) cases have been reported, probably reflecting the low level of resistance to clofazimine [28] . Based on these findings, the WHO has recommended that clofazimine be included in the multidrug therapy of XDR-TB [29] . It is noteworthy, however, that clofazimine has failed to demonstrate early bactericidal activity in the clinical setting, consistent with a relatively slow onset of antimicrobial action [18, 19, 30] .
In conclusion, the findings of the current study have demonstrated that clofazimine is active against planktonic phase and slowly replicating M. tuberculosis but is ineffective against non-replicating, biofilm-encased bacilli. This limitation underscores the importance of combination chemotherapy of TB targeting the various phases of bacterial growth.
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